National Hispanic TV Network fka GECC

[Stilgar]

That is the pattern in legal battles with Bolt

You get sued, you win. You counter sue and you win. And the end result is that you are out tens of thousands or more in legal fees and never collect a penny.

Speaking of never collecting a penny, I noticed that Bolt claimed that he first became interested in Xenavex due to his wife's cancer. I would suggest that he first became interested in another scam when he stiffed the Highlands Oncology Group for the fees for his wife's treatments and saw an opportunity to create another "enterprise which included a group of imaginary employees engaged in imaginary products and services in various imaginary locations".

After all, given their backgrounds Bolt and company were supremely qualified to create an oncology biosciences company, produce a new drug and conduct clinical trials . . .

There was no Xenavex until Bolt or his group invented the name. There was only the proven patented medicine Anvirzel and the Russian "solutio neriolini" which Dodge admitted was the source of their "Xenavex" and not a self-created product in a class 10 lab as they claimed.

Let's take a look at the proof from Shimoda itself:

First, there is this email sent by a fictitious Shimoda employee to Ozelle Pharmaceuticals:

“The Xenavex program has been more than we anticipated in terms of the challenges and outcomes.

First, the product we are working with is very similar to "solutio Neriolini." We have received sufficient input from the FDA regarding the history of this drug, their conclusions as to its prior inclusion in various pharmacopeias, etc., and how those findings are reconciled with Section 201(g)(1) of the [FD&C] Act as to proceed to a Phase II trial, using sublingual administration, all absent a formal Phase I study. We have prepared a Phase II Form 1571 to that end, and are awaiting IRB clearance. We had decided to hold back on the trial launch until a recently published paper was in fact published, describing the relationship between inflammation and NF-kB. Now that the paper has appeared in Cancer Cell, September 2004, we expect to pursue our IRB clearance shortly. I realize that you will probably find the foregoing statements to be vague, especially as to the regulatory side of things. The particular FDA regs and how they affect this unique project, are to a great extent proprietary at this time…”

Sincerely,

Alex Hardcastle, Xenavex Program Manager

ShimodaAtlantic Oncology BioSciences LLC

P.O. Box 7931
Springdale, AR 72764

479-751-4700 ext. 3
479-751-3434 (facsimile)
479-544-3113 (cell)

Note: The only Alex Hardcastle to be found in the Springdale/Bentonville area is an 86 year old man who hasn't a clue about Shimoda. But he did have a listing in a local phone book that apparently came in handy.

Next, let us take a look at excerpts from a letter sent by none other than Dodge himself:

"In fact, ShimodaAtlanticTM learned some time ago that it can purchase a finished nerium oleander L. pharmaceutical derivative, in liquid (solution Neriolini) (oleandrin 22 mg, alcohol 4 mL, distilled water to 100 mL)...from Russian manufacturers."

"...they have long since decided to go that route for the purposes of clinical evaluation of the drug in cancer cases."

from a letter to Ozelle Pharmaceuticals sent by John Dodge, representing Shimoda Atlantic in September 2004.

Any questions about the source of "Xenavex"?